Journal
CANCER LETTERS
Volume 451, Issue -, Pages 100-109Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.02.046
Keywords
DYRK2; Liver cancer; Adenovirus; Proliferation; Apoptosis
Categories
Funding
- Japan Society for the Promotion of Science (KAKENHI) [JP26290041, JP17H03584, JP16K09378]
- Takeda Science Foundation
- Bristol-Myers Squibb foundation
- SGH foundation
- Jikei University Graduate Research Found
Ask authors/readers for more resources
Liver cancer is highly aggressive and globally exhibits a poor prognosis. Therefore, the identification of novel molecules that can become targets for future therapies is urgently required. We have reported that dual-specificity tyrosine-regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, the research into its clinical application as a molecular target has remained to be explored. Here we showed that DYRK2 knockdown enhanced tumor growth of liver cancer cells. Conversely and more importantly, adenovirus-mediated overexpression of DYRK2 resulted in inhibition of cell proliferation and tumor growth, and induction of apoptosis both in vitro and in vivo. Furthermore, we found that liver cancer patients with low DYRK2 expression had a significantly shorter overall survival. Given the findings that DYRK2 regulates proliferation and apoptosis of cancer cells, DYRK2 expression could be a promising predictive marker of the prognosis in liver cancer. Stabilized or forced expression of DYRK2 may become thus a potential target for novel gene therapy against liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available